<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109520</url>
  </required_header>
  <id_info>
    <org_study_id>S65399</org_study_id>
    <nct_id>NCT05109520</nct_id>
  </id_info>
  <brief_title>Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL</brief_title>
  <acronym>FUTURE-GLARE</acronym>
  <official_title>Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL: A FUTURE Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>prof dr Pieter Gillard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective multicenter study analyzing data gathered during the FUTURE study (S59342) to&#xD;
      assess the effect of using Insulin Glargine 300 U/mL (Gla-300) on measures of diabetes&#xD;
      control and quality of life.&#xD;
&#xD;
      Of the FUTURE participants, data about the type of insulin the participants used will be&#xD;
      gathered. On the basis of these data participants will be divided in two groups (control or&#xD;
      investigational).&#xD;
&#xD;
      Change in glycemic control and quality of life from before to after the switch to Gla-300&#xD;
      (investigational group) will be compared to the change of glycemic control and quality of&#xD;
      life of the FUTURE participants who did not switch to Gla-300 (control group).&#xD;
&#xD;
      The FUTURE study was a 24-month during multicenter observational cohort study analyzing data&#xD;
      on the use of the Abbott Freestyle Libre in people with diabetes. Data were gathered during&#xD;
      standard clinical follow-up, and from questionnaires that were presented to the participants&#xD;
      at defined time points.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">October 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time in range (TIR, 70-180 mg/dL)</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>The difference in evolution of TIR (70-180 mg/dL, averaged per month) over 24 hours since switch to Gla-300</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in range (TIR, 70-180 mg/dL)</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in TIR (70-180 mg/dL, averaged per month) from 6 am to 10 pm, and from 10 pm to 6 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in time in hypoglycemia (&lt;54 mg/dL, &lt;70 mg/dL, ≥54-&lt;70 mg/dL; averaged per month) over 24 hours, from 6 am to 10 pm, and from 10 pm to 6 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in time in hyperglycemia (&gt;180 mg/dL, &gt;250 mg/dL, &gt;180-≤250 mg/dL; averaged per month) over 24 hours, from 6 am to 10 pm, and from 10 pm to 6 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glycemia</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in mean glucose (averaged per month) over 24 hours, from 6 am to 10 pm, and from 10 pm to 6 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in glycemic variability (standard deviation, coefficient of variation; averaged per month) over 24 hours, from 6 am to 10 pm, and from 10 pm to 6 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by the Short Form Health Survey 36-item (SF-36) version 2 questionnaire</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>Quality of life measured by the Short Form Health Survey 36-item (SF-36) version 2 questionnaire (scale: 0 (low quality of life) - 100 (high quality of life))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of hypoglycemia measured by the Hypoglycemia Fear Survey, version II (HFS-II) questionnaire, worry</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>Fear of hypoglycemia measured by the Hypoglycemia Fear Survey, version II (HFS-II) questionnaire, worry (scale: 0 (not worried) - 72 (very worried))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress due to diabetes measured by the Problem Areas In Diabetes survey, short form (PAID-SF) questionnaire</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>Distress due to diabetes measured by the Problem Areas In Diabetes survey, short form (PAID-SF) questionnaire (scale: 0 (no distress) - 20 (very distressed))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire, status (DTSQs)</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>Treatment satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire, status (DTSQs) (scale: 0 (low satisfaction) - 36 (high satisfaction))</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin dose</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in insulin dose (basal, bolus and total)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in body mass index (BMI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe hypoglycemia rate</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in self-reported severe hypoglycemic events</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemic coma rate</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in self-reported hypoglycemic comas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalization</measure>
    <time_frame>maximum 24 months</time_frame>
    <description>difference in hospitalizations due to hypoglycemia or ketoacidosis</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">867</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>investigational group</arm_group_label>
    <description>Participants of the FUTURE study who switched during the study to Gla-300</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Participants of the FUTURE study who did not switch to Insulin Gla-300</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 300 UNT/ML [Toujeo]</intervention_name>
    <description>Switch during standard routine care to Gla-300.</description>
    <arm_group_label>investigational group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People with type 1 diabetes who participated in the FUTURE study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Investigational group&#xD;
&#xD;
             Inclusion Criteria:&#xD;
&#xD;
               -  participant in the FUTURE study&#xD;
&#xD;
               -  diagnosed with type 1 diabetes ≥3 months before start of the FUTURE study&#xD;
&#xD;
               -  use of insulin pens for the entirety of the FUTURE study&#xD;
&#xD;
               -  used Insulin Detemir (Levemir®), Insulin Glargine 100 U/mL (Lantus®) or an&#xD;
                  equivalent as basal insulin before switch to Gla-300 (Toujeo®)&#xD;
&#xD;
               -  switched to Gla-300 (Toujeo®) during the FUTURE study for a sufficient amount of&#xD;
                  time (at least two consecutive diabetes consultations = 8 months)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  use of Fast-acting insulin aspart (Fiasp®) before or after switch to Gla-300&#xD;
&#xD;
               -  not using bolus insulin (only basal insulin)&#xD;
&#xD;
               -  for women: pregnant or planning pregnancy during the FUTURE study&#xD;
&#xD;
          2. Control group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  participant in the FUTURE study for at least 18 months&#xD;
&#xD;
          -  diagnosed with type 1 diabetes ≥3 months before start of the FUTURE study&#xD;
&#xD;
          -  use of insulin pens for the entirety of the FUTURE study&#xD;
&#xD;
          -  use Insulin Detemir (Levemir®), Insulin Glargine 100 U/mL (Lantus®) or an equivalent&#xD;
             as basal insulin during the entirety of the FUTURE study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use of Fast-acting insulin aspart (Fiasp®)&#xD;
&#xD;
          -  not using bolus insulin (only basal insulin)&#xD;
&#xD;
          -  for women: pregnant or planning pregnancy during the FUTURE study&#xD;
&#xD;
          -  switch to Gla-300 (Toujeo®) or Insulin Degludec (Tresiba®) before 18 months in FUTURE&#xD;
             study (if switched after 18 months, only data up to switch to Gla-300 [Toujeo®] or&#xD;
             Insulin Degludec [Tresiba®] will be used for this control participant)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Gillard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>prof dr Pieter Gillard</investigator_full_name>
    <investigator_title>Principal Investigators</investigator_title>
  </responsible_party>
  <keyword>Insulin Glargine 300 U/mL</keyword>
  <keyword>Continuous glucose monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD can be shared upon a genuine request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

